Core Viewpoint - Prime Mining Corp. is advancing its Preliminary Economic Assessment (PEA) for the Los Reyes gold-silver project, targeting completion in Q3 2025, with a focus on high returns, low capital costs, and long project life [1][2][3] Company Overview - Prime Mining has invested over $64 million in direct exploration activities since acquiring Los Reyes in 2019, completing over 221,000 meters of drilling [2][7] - The company aims to enhance its resource base through exploration and technical de-risking activities [20] Project Details - The PEA will be based on drilling data up to the end of 2024 and will incorporate extensive technical work completed to date [2] - The project is characterized as a high-grade, low-sulphidation epithermal gold-silver project located in Sinaloa State, Mexico [7] - The PEA is expected to highlight a project with high returns, high margins, low capital requirements, and a long operational life [2][7] Exploration Plans - Six drill rigs are currently operational at Los Reyes, with plans to extend high-grade mineralization and identify new prospective targets [5] - Planned activities include geological mapping, geochemical sampling, and drilling in areas with high-grade intercepts [5] Community Engagement - The company is committed to engaging with local communities through educational and environmental programs, as well as infrastructure development [5] Technical Expertise - Ausenco Engineering Canada ULC has been selected to lead the PEA due to its extensive experience with similar projects in Mexico [3][4]

Group 1 - Tenaris S.A. announced a share buyback program of up to $1.2 billion, representing approximately 74 million shares or 6.9% of its outstanding shares [1] - The buyback program is driven by significant cash flow generation and a strong balance sheet, with a maximum limit of 10% of the company's shares [2] - The program is expected to launch in June 2025 and will be executed through a primary financial institution [2] Group 2 - The buybacks may be paused or ceased at any time, subject to compliance with applicable laws and regulations [3] - Updates on the buyback program will be provided via press releases and on the Investors section of Tenaris's corporate website [3] - The buybacks will be conducted in compliance with the Market Abuse Regulation and other relevant regulations [3] Group 3 - Tenaris is a leading global supplier of steel tubes and related services for the energy industry and other industrial applications [5]

SummaryHavila Kystruten delivered further improvements in both revenue and profitability in the first quarter of 2025. The company reported a strengthened operating result (EBITDA), primarily driven by top-line growth. In Q1 2025, Havila Kystruten generated revenues of MNOK 350, an increase of 20% from MNOK 293 in the same period last year. The growth was mainly due to a 35% increase in average cabin revenue (ACR), which rose from NOK 3,350 to NOK 4,600. Onboard sales per guest night remained stable compare ...

The board of directors of Havila Kystruten AS has today approved the financial statements and annual report for 2024, which integrates financial and sustainability reporting. The report is attached in PDF format. It summarizes the year and highlights the company's fundamental focus on the environment and sustainability. Contacts:Chief Executive Officer: Bent Martini, +47 905 99 650Chief Financial Officer: Aleksander Røynesdal, +47 413 18 114 This information is subject to the disclosure requirements pursu ...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) announces that it has granted an additional 633,589 restricted share units (“RSUs”) and 330,132 stock options (“Options”) to continuing employees and consultants of Rocket Doctor Inc., the Company’s wholly-owned subsidiary (see News Release dated April 10, 2025). The ...

MARKHAM, Ontario, May 27, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced the results of matters voted on at its annual and special meeting of shareholders held on May 27, 2025 (the “Meeting”). The voting results for each of the matters considered at the Meeting are presented below. The total number of common shares represented by shareholders present in person or by proxy at the Meeting was 47,282,730, representing 56.41% of the Company’s outstanding c ...

Core Viewpoint - Teva Pharmaceutical Industries has received Fast Track designation from the FDA for its investigational anti-IL-15 antibody, TEV-53408, aimed at treating celiac disease, highlighting the urgent need for effective treatments in this area [1][3][7]. Company Overview - Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader with over 120 years of experience, focusing on innovation and the development of medicines, including generics and biologics, to improve health outcomes [6]. Product Development - TEV-53408 is currently undergoing a Phase 2a trial to evaluate its efficacy and safety in adults with celiac disease, which affects approximately 1% of the global population [1][4][5]. - The drug works by inhibiting interleukin-15 (IL-15), which is responsible for the immune response to gluten, thereby aiming to reduce intestinal inflammation and damage in celiac disease patients [3][4]. Market Need - Celiac disease is a chronic autoimmune disorder that significantly impacts quality of life, with the only current treatment being a strict gluten-free diet, which many patients struggle to adhere to [5]. - There is a significant unmet medical need for new treatment options, as many patients continue to experience debilitating symptoms even on a gluten-free diet [3][5].

TORONTO, May 27, 2025 (GLOBE NEWSWIRE) -- Captor Capital Corp. (“Captor” or the “Company”) (CSE: CPTR) is excited to announce a significant milestone in its growth strategy with the acquisition of US$500,000 in Bitcoin for treasury holdings and the issuance of unsecured convertible loan notes (the “Notes”) in the aggregate amount of US$450,000 to a European-based institutional investor (the “Noteholder”). These strategic moves reinforce Captor’s commitment to innovative financial strategies and delivering e ...

Net Income Increased by 17.3% Compared to Q1/2024CALGARY, Alberta, May 27, 2025 (GLOBE NEWSWIRE) -- Tornado Infrastructure Equipment Ltd. (“Tornado” or the “Company”) (TSX-V: TGH; OTCQX: TGHLF) today reported its unaudited condensed consolidated financial results for the three months period ended March 31, 2025. The unaudited condensed consolidated financial statements and related management discussion and analysis are available on the Company’s issuer profile in Canada on SEDAR+ at www.sedarplus.com, in th ...

Monterey, CA , May 27, 2025 (GLOBE NEWSWIRE) -- ChampionsGate Acquisition Corporation (Nasdaq: CHPGU) (the “Company”) announced today the pricing of its initial public offering of 6,500,000 units at $10.00 per unit. The units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “CHPGU” beginning May 28, 2025. Each unit consists of one Class A ordinary share and one right to receive one-eighth of one Class A ordinary share. Once the securities comprising the unit ...